middle.news
Mayne Pharma’s Women’s Health engine gains traction despite a sharp EBITDA decline
8:49am on Monday 26th of October, 2026 AEDT
•
Pharmaceuticals
Read Story
Mayne Pharma’s Women’s Health engine gains traction despite a sharp EBITDA decline
8:49am on Monday 26th of October, 2026 AEDT
Key Points
Underlying EBITDA fell 52% to A$5.3 million
Women’s Health prescriptions rose across BIJUVA, IMVEXXY and NEXTSTELLIS
Generic RHOFADE entry drove lower Dermatology sales and margins
DistributeRx prescriptions increased 120% to 84,000
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE